Opioid Crisis: A National Public Health Emergency
President Trump on October 26, 2017, directed the Department of Health and Human Services to declare the opioid crisis a public health emergency, taking long-anticipated action to address a rapidly escalating epidemic of drug use. The United States is in the middle of an unprecedented opioid epidemic; Since 2000, the rate of overdose deaths involving opioids nearly quadrupled, and over 165,000 people have died from prescription opioid overdoses. Prevention, treatment, and research to rapidly tackle and reverse opioid overdoses are critical to fighting this epidemic. Data is showing that on an average day in the US about 140 people die from an opioid-related overdose, most of the ones died belongs to the younger population.
Studies have shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior. Biotica’s preliminary studies have shown that cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. Biotica has been developing various cannabinoid formulations for relieving various pains and opioid withdrawal symptoms. There is strong evidence that cannabinoid compounds can relieve depression caused by drug addiction.
BPRxTM-060312 Biotica’s initiative on Opioid Addiction
BPRxTM-0603122 is a cannabidiol based cannabinoid formulation recently developed by Biotica that represents a select combination of phytocannabinoids assembled to specifically target opioid. Biotica has identified a combination of patent-pending drug actives – BPRxTM-060312 which targets and blocks rewarding neuronal effects. BPRxTM-060312 is a proprietary formulation of cannabinoids.